Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Bayesian multivariate linear mixed-effects models with varied association structures.

Statistical methods in medical research·2026
Same author

Managing Pompe Disease and Enzyme Replacement Therapy During Pregnancy: Challenges and Considerations.

European journal of neurology·2026
Same author

Quantitative Muscle MRI of the Lower Extremities Reveals Different Patterns of Involvement in Classic Infantile and Young Late-Onset Pompe Patients.

Journal of inherited metabolic disease·2026
Same author

Unfavorable cardiovascular risk profile without increased event prevalence in late-onset Pompe disease: an individually matched cohort study.

Orphanet journal of rare diseases·2026
Same author

Population Pharmacokinetic/Pharmacodynamic Modeling of Therapeutic Enzymes in Lysosomal Storage Diseases.

Clinical pharmacokinetics·2026
Same author

Antibody formation and efficacy of enzyme replacement therapy in adults with Pompe disease: Unlocking long-term insights.

Genetics in medicine : official journal of the American College of Medical Genetics·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Ver todos los artículos relacionados

Video Experimental Relacionado

Updated: Jun 28, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

La enfermedad de Pompe.

Ans T van der Ploeg1, Arnold J J Reuser

  • 1Department of Paediatrics, Division of Metabolic Diseases and Genetics, Erasmus MC, Sophia Children's Hospital, University Medical Centre, Rotterdam, The Netherlands. a.vanderploeg@erasmusmc.nl

Lancet (London, England)
|October 22, 2008
PubMed
Resumen
Este resumen es generado por máquina.

La enfermedad de Pompe es un trastorno genético raro que causa la acumulación de glucógeno en los lisosomas. La terapia de reemplazo enzimático ha mejorado significativamente las opciones de tratamiento para este trastorno metabólico y muscular progresivo.

Más Videos Relacionados

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Tissue Triage and Freezing for Models of Skeletal Muscle Disease
05:58

Tissue Triage and Freezing for Models of Skeletal Muscle Disease

Published on: July 15, 2014

Videos de Experimentos Relacionados

Last Updated: Jun 28, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Tissue Triage and Freezing for Models of Skeletal Muscle Disease
05:58

Tissue Triage and Freezing for Models of Skeletal Muscle Disease

Published on: July 15, 2014

Área de la Ciencia:

  • La bioquímica es la bioquímica.
  • Genética La genética.
  • La pediatría es la medicina de los niños.

Sus antecedentes:

  • La enfermedad de Pompe, también conocida como enfermedad de almacenamiento de glucógeno tipo II o deficiencia de maltasa ácida, es un trastorno metabólico autosómico recesivo panétnico.
  • Se caracteriza por una deficiencia en la enzima ácido alfa-glucosidasa, lo que lleva a la acumulación de glucógeno dentro de los lisosomas.
  • Este almacenamiento generalizado de glucógeno afecta a múltiples sistemas de órganos, afectando principalmente a la función muscular y conduciendo a la movilidad progresiva y problemas respiratorios.

Objetivo del estudio:

  • Proporcionar una visión global de la enfermedad de Pompe, que abarca su fisiopatología, espectro clínico y enfoques de diagnóstico.
  • Para resaltar los avances significativos en la atención al paciente, en particular el desarrollo y la aprobación de la terapia de reemplazo enzimático (ERT).
  • Para discutir los últimos conocimientos sobre los mecanismos de la enfermedad y las estrategias terapéuticas emergentes.

Principales métodos:

  • Revisión de la literatura existente sobre la enfermedad de Pompe, incluyendo estudios genéticos, bioquímicos y clínicos.
  • Análisis del desarrollo histórico y aprobación regulatoria de la terapia de reemplazo enzimático (alglucosidasa alfa).
  • Discusión de las prácticas clínicas actuales y las direcciones futuras en el manejo de la enfermedad de Pompe.

Principales resultados:

  • La enfermedad de Pompe presenta un amplio espectro clínico, afectando a los individuos desde la infancia hasta la edad adulta, siendo la hipertrofia cardíaca un sello distintivo de la forma infantil.
  • El advenimiento de la terapia de reemplazo enzimático (ERT) con alglucosidasa alfa, aprobada en 2006, ha transformado el panorama del tratamiento, ofreciendo un medio para mitigar la progresión de la enfermedad.
  • Este avance terapéutico coloca la enfermedad de Pompe entre un grupo creciente de trastornos de almacenamiento lisosómico con tratamientos disponibles.

Conclusiones:

  • La terapia de reemplazo enzimático representa un gran avance en el manejo de la enfermedad de Pompe, mejorando significativamente los resultados de los pacientes.
  • La investigación continua sobre la fisiopatología de la enfermedad y las intervenciones terapéuticas es crucial para mejorar aún más la atención de las personas con enfermedad de Pompe.
  • La sensibilización y la difusión de los últimos conocimientos sobre el diagnóstico y la gestión son esenciales para optimizar la atención al paciente y los resultados.